Multaq / Dronedarone causing liver failure amongst its users

The French pharmaceutical company Sanofi-Aventis, has confirmed that two users of its atrial fibrillation drug, Multaq ( Dronedarone) now require transplants following liver failure.   The drug was first approved for use in the United States in July of 2009.

Dronedarone is used to treat abnormal heart rhythm in patients who have had atrial fibrillation or atrial flutter during the past six months. Dronedarone can reduce the risk of being hospitalized for these conditions, according to the FDA. The agent was approved with a Risk Evaluation and Mitigation Strategy with a goal of preventing its use in patients with severe heart failure or who have recently been in the hospital for heart failure. In a study of patients with these conditions, patients given dronedarone had a greater than two-fold increase in risk of death. Link

Link to the Wall Street Journal Article

If you, or someone you know, has taken Multaq / Dronedarone and suffered any sort of complication, it is important to know your rights.  Please CONTACT an attorney to evaluate your case and advise you as to how you may proceed.

 

If you or someone you know is currently taking Multaq ( Dronedarone ) please advise them to contact their doctor immediately to discuss their situation.  If you have been injured while taking Multaq ( Dronedarone ), please CONTACT us immediately for a free case consultation.  The Ronan Law Firm has over 25 years of litigation experience and we have successfully represented clients all across the nation in pharmaceutical cases such as Vioxx, Fen-Phen, Avandia and more.

 

Why let uncertainty prevent you from proper recovery for your injury?  CONTACT the Ronan Law Firm with any questions or concerns that you may have.